COVID-19 VACCINES FOR CHILDREN UNDER 5: WHAT WE KNOW NOW

Information on timelines, ordering, available clinical considerations, etc.*

Thurs, June 9, 2022 at 12 pm
& Fri, June 17, 2022 at 12 pm

REGISTER AT ILLINOISAAP.ORG/EVENTS

*Pending approval
Heidi Clark, MPH – Illinois Department of Public Health

Karyn Lyons, MS, RN – Illinois Department of Public Health

Kevin Hansen – Chicago Department of Public Health

Felicia Scott-Wellington, MD – Department of Pediatrics at University of Illinois Health

Viktoria De Jong – Chicago Department of Public Health

Speakers
Resources Available
COVID-19 VACCINES FOR YOUNGER CHILDREN

Communication & Planning Toolkit

Available here
Illinois Vaccinates Against COVID-19

- Bootcamps
- Learning collaboratives
- Implementation support
- Outreach materials
- Toolkit
- Podcast
- And more

illinoisvaccinates.com
Upcoming Events

• Tuesday, 6/21 at 12pm - Where We Are Now with Routine Pediatric Vaccination Coverage featuring TikTok sensation, Zachary Rubin. Dr. Rubin is a double board-certified pediatrician specializing in allergy and immunology. CME available.

• Tuesday, 6/21 at 5:30pm – I-VAC Learning Collaborative - Pediatric Populations. CME available.

Register at illinoisaap.org/events
Pediatric COVID-19 Vaccines for Children 6-Month to 5-Years of Age
Training Supplement

June 17, 2022
Information current as of June 16, 2022

- Information shared is most up to date information we have from CDC.
- Information is subject to change based on evolving CDC guidance.
- The vaccine formulations in this presentation are not yet ACIP Recommended.
- IDPH will continue to provide information to providers through SIREN alerts.

- This presentation is not meant to be a complete training. Additional trainings are required and are shown later in this slide deck.
Announcements
Recent Pediatric VRBPAC Votes

- June 14, 2022
  - VRBPAC recommends authorization of Moderna COVID-19 vaccine for children 6 through 17 years of age
    - 100 microgram dose for 12- through 17-year-olds
    - 50 microgram dose for 6- through 11-year-olds
  - FDA Authorization announcement published on 6/17/2022
  - No ACIP vote yet
  - The vaccine formulations in this presentation are not yet ACIP Recommended. Do not administer these products until CDC has endorsed the use of this product.
Recent Pediatric VRBPAC Votes

• June 15, 2022
  – VRBPAC recommends authorization of Moderna COVID-19 vaccine for children 6 months through 5 years of age. [Click here for slides.]
    • 25 microgram dose for 6-month- through 5-year-olds
    • 2 dose series, 1 month apart
  – VRBPAC recommends authorization of Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 years of age. [Click here for slides.]
    • 3 microgram dose for 6-month- through 4-year-olds
    • 3 dose series
    • Three-week interval between doses 1 and 2, followed by an 8 week interval between doses 2 and 3.
  – FDA Authorization announcement published on 6/17/2022
  – On ACIP agenda - Friday, June 17 through Saturday, June 18
  – Do not administer these products until CDC has endorsed the use of these products.
Preparing for Rollout
Preparing for rollout

• Prepare all in your practice for rollout.
• Communicate with parents about expectations and address COVID-19 vaccine hesitancy.
• Ensure staff are trained on the specifics of each vaccine available at your facility.
• Ensure staff are equipped and trained to respond to possible severe allergic reactions. Carry age-appropriate emergency supplies on hand.
• Consider co-administration of COVID-19 vaccines with other childhood vaccines, when appropriate.
Talking to Parents about COVID-19 Vaccination

- How to Talk with Parents about COVID-19 Vaccination web page provides information about the benefits of vaccination, vaccine coadministration, vaccine confidence, and more.

Resources to Promote the COVID-19 Vaccine for Children & Teens
Pediatric Vaccine Reporting on Vaccines.gov

Weekly inventory updates are required:
- New vaccines will be available to add as inventory in the COVID Locating Health Portal once they are authorized.
- Use the “Add Vaccine” option to add NDCs to your location.

Public View:
- Vaccines.gov will include a search field for new formulations once authorized.

Find the instruction guides on the Provider Resources page.
Formulations and Packaging

Summary of Future Formulations for Children:

Pfizer-BioNTech COVID-19 Vaccine for Children 6m-4y

and

Moderna COVID-19 Vaccine for Children 6m-5y
## Potential Pediatric COVID-19 Vaccine Product Details*

<table>
<thead>
<tr>
<th>Manufacturer/Vial</th>
<th>Vaccine Age Range</th>
<th>Vaccine Dosing</th>
<th>Storage and Other Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer-BioNTech</td>
<td>6 months through 4 years</td>
<td>3 micrograms/0.2mL, 2.2mL diluent required, 3 Dose Primary Series</td>
<td>Ships at -80°C&lt;br&gt;For details, see <a href="#">Pfizer BioNTech COVID-19 Vaccine Products</a></td>
</tr>
<tr>
<td>10 doses per vial</td>
<td><strong>MAROON</strong> Cap Vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderna</td>
<td>6 months through 5 years</td>
<td>25 micrograms/0.25mL, NO diluent required, 2 Dose Primary Series</td>
<td>Ships at -20°C&lt;br&gt;A document with details on this vaccine is being developed</td>
</tr>
<tr>
<td>10 doses per vial</td>
<td><strong>BLUE</strong> Cap Vial with a magenta border</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Subject to change pending submission of applications, emergency use authorization(s), and CDC recommendation(s).*
### Storage & Handling Pfizer-BioNTech

<table>
<thead>
<tr>
<th></th>
<th><strong>Current Products</strong></th>
<th><strong>Future Product</strong> Authorization Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age Indications</strong></td>
<td>5 through 11 years</td>
<td>6 months through 4 years</td>
</tr>
<tr>
<td><strong>Formulation</strong></td>
<td>Primary Series and Booster Dose</td>
<td>Primary Series</td>
</tr>
<tr>
<td><strong>Vial Cap Color/Label with Color Border</strong></td>
<td>ORANGE</td>
<td>MAROON</td>
</tr>
<tr>
<td><strong>Preparation</strong></td>
<td>Dilute Before Use</td>
<td>Dilute Before Use</td>
</tr>
<tr>
<td><strong>Amount of Diluent Needed per Vial</strong></td>
<td>1.3 mL</td>
<td>2.2 mL</td>
</tr>
<tr>
<td><strong>Dose Volume/Dose</strong></td>
<td>0.2 mL/10 mcg</td>
<td>0.2 mL/3 mcg</td>
</tr>
<tr>
<td><strong>Doses per Vial</strong></td>
<td>10 (after dilution)</td>
<td>6</td>
</tr>
<tr>
<td><strong>ULT Freezer</strong> (-90°C to -60°C)**</td>
<td>12 months</td>
<td>12 months</td>
</tr>
<tr>
<td><strong>Freezer (-25°C to -15°C)</strong></td>
<td>DO NOT STORE</td>
<td>DO NOT STORE</td>
</tr>
<tr>
<td><strong>Refrigerator</strong> (2°C to 8°C)</td>
<td>10 weeks</td>
<td>10 weeks</td>
</tr>
<tr>
<td><strong>Room Temperature</strong></td>
<td>12 hours prior to first puncture</td>
<td>12 hours prior to first puncture</td>
</tr>
<tr>
<td><strong>including any thaw time</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>After First Puncture</strong></td>
<td>(2°C to 25°C)</td>
<td>Discard after 12 hours</td>
</tr>
<tr>
<td></td>
<td><strong>Discard after 12 hours</strong></td>
<td></td>
</tr>
</tbody>
</table>

*a* Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

*b* Regardless of storage condition, vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.
Additional Storage and Handling information:

• Once product is thawed, do not refreeze.
• The 10 weeks in the refrigerator is **not** in addition to the overall expiration date for vaccine stored in the ultra-low freezer.
• Expired vaccine should be discarded regardless of storage conditions.
• Do not store **Maroon** cap vaccine in a standard freezer.
Pfizer-BioNTech Maroon Cap and Label

- Pediatric vials come packaged in cartons of 10 vials each. Each vial contains 10 doses after dilution.
- Vials come with a distinctive maroon coloration:
  - maroon cap
  - maroon striping on the vial label
  - maroon striping on the carton

Label Characteristics
Maroon Cap Ages 6 months through 4 years

If authorized by the FDA, Maroon Cap vaccine vials and cartons you receive will be labeled as Pfizer-BioNTech COVID-19 Vaccine.

Initial shipments of Maroon Cap vials and cartons will have the following label characteristics:

- The vial labels may state: Age 2y to < 5y or Age 6m to < 5y
- Carton labels may state: For age 2 years to < 5 years or For age 6 months to < 5 years.
- Vials with either printed age range can be used for individuals 6 months through 4 years of age*

*If the product is authorized for the entire age range
Manufacturer versus Expiration Date

• The date on the maroon cap vial is the date of manufacture, not the expiration date.
• To check the expiration date, use this resource (to be updated when the vaccine is available): expiry-doc (pfizer.com)
Pfizer-BioNTech COVID-19 Shippers

- Pfizer maroon cap vaccine will ship from Pfizer on dry ice.
- These shippers cannot be used for temporary storage.
- The contents MUST be removed from the shipper and placed in an **ultra-cold freezer** or a **refrigerator** as soon as it is received.
Controlant Data Logger

• Shipping boxes will continue to contain a Controlant temperature monitor.
• Check the temperature monitor for any excursion warnings, turn the monitor off, and return it in the package provided.
• Be sure to add these sites to your safe sender lists so that you receive order, shipping, and temperature monitoring alerts:
  – cvgovernment@pfizer.com
  – Pfizer.logistics@controlant.com
  – onsitemonitoring@controlant.com
## Storage & Handling Moderna

<table>
<thead>
<tr>
<th>Current Moderna Products</th>
<th>Future Moderna Product(s) Authorization Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age Indications</strong></td>
<td>18 years and older</td>
</tr>
<tr>
<td><strong>Formulation</strong></td>
<td>Primary Series and Booster Dose</td>
</tr>
<tr>
<td><strong>Vial Cap Color/Label with Color Border</strong></td>
<td>Red cap, blue label border 5.5 mL</td>
</tr>
<tr>
<td><strong>Preparation</strong></td>
<td>Do Not Dilute</td>
</tr>
<tr>
<td><strong>Dose Volume/Dose</strong></td>
<td>0.5 mL/100 mcg primary 0.25 mL/50 mcg booster</td>
</tr>
<tr>
<td><strong>Doses per Vial</strong></td>
<td>11 max primary doses or 20 booster doses</td>
</tr>
<tr>
<td><strong>ULT Freezer (-90°C to -60°C)</strong></td>
<td>DO NOT STORE</td>
</tr>
<tr>
<td><strong>Freezer (-25°C to -15°C)</strong>*</td>
<td>Until Expiration</td>
</tr>
<tr>
<td><strong>Refrigerator (2°C to 8°C)</strong></td>
<td>30 Days</td>
</tr>
<tr>
<td><strong>Room Temperature (8°C to 25°C) including any thaw time</strong></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>After First Puncture (2°C to 25°C)</strong></td>
<td>Discard after 12 hours</td>
</tr>
<tr>
<td><strong>Future Moderna Product(s)</strong></td>
<td>6 months through 17 years?</td>
</tr>
<tr>
<td><strong>Future Moderna Product(s)</strong></td>
<td>Blue cap, purple label border</td>
</tr>
<tr>
<td><strong>Future Moderna Product(s)</strong></td>
<td>Do Not Dilute</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Regardless of storage condition, vaccines should not be used after the expiration date.*
Moderna COVID-19 Vaccine Cold-Chain

Additional storage and handling information:

• Once product is thawed, do not refreeze.
• The 30 days in the refrigerator is **not** in addition to the overall expiration date for vaccine stored in the ultra-low freezer.
• Expired vaccine should be discarded regardless of storage conditions.
Moderna COVID-19 Vaccine Expiration Date

• There is no expiration date printed on the Moderna vials or cartons.
• Look up the expiration date for each lot number at this [webpage](#).
**Primary Doses <18**

<table>
<thead>
<tr>
<th><strong>Current Products</strong></th>
<th><strong>Future Products</strong></th>
<th><strong>Authorization Pending</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccine Manufacturer</strong></td>
<td>Pfizer-BioNTech</td>
<td>Pfizer-BioNTech</td>
</tr>
<tr>
<td><strong>Age Indications</strong></td>
<td>5 through 11 years</td>
<td>12 years and older</td>
</tr>
<tr>
<td><strong>Vial Cap Color/Label with Color Border</strong></td>
<td>Orange</td>
<td>Gray</td>
</tr>
<tr>
<td><strong>Preparation</strong></td>
<td>Dilute Before Use</td>
<td>Do Not Dilute</td>
</tr>
<tr>
<td><strong>Amount of Diluent Needed per Vial</strong></td>
<td>1.3 mL</td>
<td></td>
</tr>
<tr>
<td><strong>Dose Volume/Dose</strong></td>
<td>0.2 mL/10 mcg</td>
<td>0.3 mL/30 mcg</td>
</tr>
<tr>
<td><strong>Number of doses for people who are NOT immune compromised</strong></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>Interval between doses</strong></td>
<td>3-8 weeks*</td>
<td>3-8 weeks*</td>
</tr>
<tr>
<td><strong>Number of doses for people who ARE immune compromised</strong></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>Interval between doses for people who ARE immune compromised</strong></td>
<td>3-8 weeks between shots 1 and 2</td>
<td>3-8 weeks between shots 1 and 2</td>
</tr>
</tbody>
</table>

*An 8-week interval may be optimal for some people ages 5 years and older, especially for males ages 12–39 years. A shorter interval (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual’s higher risk for severe disease.

Clinical Consideration Resources
Pediatric Clinical Considerations

• Review all changes in the Interim Clinical Considerations for Use of COVID-19 Vaccines and related job aids.

• Review all formula-specific information at the U.S. COVID-19 Vaccine Product Information | CDC pages.

• Review information at the Manufacturer websites.

• In the days following CDC endorsement of the ACIP recommendations, the following are expected to be updated:

  • Interim Clinical Consideration and related job aids
  • EUA Fact Sheets and Prescribing Information
  • Pfizer Training Module
  • Prevaccination Screening Form
  • Dosage Chart
  • Standing Orders
  • Storage and Handling Labels
  • Beyond Use Labels
CDC COVID-19 Vaccine Web Page for Parents and Guardians

- Information for parents and guardians [here](#).

Site includes information on COVID-19 vaccine benefits, safety, side effects, and where to find a vaccine.

COVID-19 Vaccines for Children and Teens

About Vaccination for Children and Teens

CDC recommends COVID-19 vaccines, including boosters, for everyone ages 5 years and older. Use CDC’s [COVID-19 booster tool](#) to learn if and when your child or teen can get boosters to stay up to date with their COVID-19 vaccines.

- [Vaccines for Children and Teens](#)
- [Why Children and Teens Should Get Vaccinated](#)
- [Vaccine Safety in Children and Teens](#)
Training
Pfizer-BioNTech Medical Information Sessions

- Medical information sessions for the Pfizer-BioNTech COVID-19 Vaccines, including the Maroon cap vaccine will continue to be offered three days per week on a regular basis.
- From June 20th through July 8th (except July 4th), trainings will be held 5 days per week.
- Links to each session are available here.
Moderna Medical Information Sessions

• Medical information sessions for the Moderna COVID-19 Vaccines, will be offered for 4 weeks starting June 21st.
• Moderna will also offer several Office Hours sessions for the first 6 weeks after authorization is granted.
• Invitations are forthcoming.
Required Training and Education

- A variety of healthcare professionals and personnel will be needed to implement COVID-19 vaccination efforts. These include:
  - Experienced vaccinators (administered vaccine within past 12 months)
  - Vaccinators with past experience (administered vaccine >12 months ago)
  - Medical support staff qualified to prepare, store, handle, or transport vaccine
  - Administrative support staff qualified to store, handle, or transport vaccine

- See Chart for Training Competencies by professional qualification

- Some trainings are pending pediatric dose updates. Changes are expected in the coming days after ACIP recommendation.

- Complete the COVID-19 Vaccine Administration Competencies Assessment Form (CDC) for each staff member. Providers will be required to show documentation when a site visit is performed.
# COVID-19 Vaccine Training and Core Competencies by Professional Qualification

<table>
<thead>
<tr>
<th>Training or Core Competency</th>
<th>Healthcare professionals who have administered vaccine in the last 12 months</th>
<th>Healthcare professionals who are licensed to administer COVID-19 vaccine but have not done so in the last 12 months</th>
<th>Vaccination support workers (not licensed to administer vaccine) qualified to prepare, store, handle, or transport vaccine</th>
<th>Administration support staff qualified to store, handle, or transport vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CDC Training Module(s)</strong> for the vaccine product(s) in your facility</td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td><strong>You Call the Shots: Vaccine Administration</strong> or other vaccine administration training completed within the last 12 months.</td>
<td>Required</td>
<td>Required</td>
<td>If preparing vaccine</td>
<td></td>
</tr>
<tr>
<td><strong>You Call the Shots: Vaccine Storage and Handling</strong> or other vaccine storage and handling training completed within the last 12 months.</td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td>Relevant information contained in the EUA Fact Sheet(s) for Healthcare Providers for the vaccine product(s) in your facility.</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
</tr>
<tr>
<td><strong>Clinical considerations</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Storage and handling requirements</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
</tr>
<tr>
<td><strong>Transport guidance</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
</tr>
<tr>
<td><strong>Preparation requirements</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td></td>
</tr>
<tr>
<td><strong>Administration requirements</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td></td>
</tr>
<tr>
<td><strong>Anaphylaxis guidance</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td></td>
</tr>
<tr>
<td><strong>Vaccination documentation and reporting requirements</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
</tr>
<tr>
<td><strong>Vaccine recipient education</strong></td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
<td>Core Competency</td>
</tr>
</tbody>
</table>
Adverse Events and Managing Anaphylaxis
Preparing for Management of Anaphylaxis


• Assure that staff are trained to recognize and respond to anaphylaxis in children in all age groups.
• Facilities should ensure they have **age and size appropriate** emergency supplies on hand.
• Epinephrine, including autoinjectors and aqueous solutions, should be procured through your usual supply chain vendors. They will not be available through state or federal resources.
Encourage Enrollment in V-safe

- **V-safe** is a smartphone app for reporting any side effects after getting the COVID-19 vaccine directly to the CDC.
- Parents or Guardians may enroll vaccinated children in v-safe.
Vaccine Adverse Event Reporting System

Have you had a reaction following a vaccination?

1. Contact your healthcare provider.
2. Report an Adverse Event using the VAERS online form or the downloadable PDF. New!

Important: If you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 9-1-1. CDC and FDA do not provide individual medical treatment, advice, or diagnosis. If you need individual medical or health care advice, consult a qualified healthcare provider.

COVID-19 vaccine EUA reporting requirements for Providers

vaers.hhs.gov/
VAERS Reporting

Healthcare providers are **required** to report the following adverse events to VAERS:

- vaccine administration errors whether or not associated with an adverse event,
- serious adverse events‡ (irrespective of attribution to vaccination),
- cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and
- cases of COVID-19 that result in hospitalization or death.

‡See EUA Fact Sheet for Providers for definition of serious adverse events

Find detailed Information on reporting requirements [here](#).
Complete and submit reports to VAERS online [here](#).
Preventing Errors
Preventing Errors: Select Correct Vial for Age

• Check the vial label 3 TIMES to assure that you are administering the appropriate product for the patient age:
  – For Pediatric patients 6 months through 4 years of age, verify that the vial of Pfizer-BioNTech COVID-19 Vaccine has a maroon plastic cap and a label with a maroon border and states "Age 6m to <5y."
  – Note: early deliveries may contain vials with labels stating “2y to <5y.”
Preventing Errors: Considerations for Time Outs & The 5 “Rights”

• Use a Time Out strategy
• More than one staff should inspect the vaccine vial for correct reconstitution, dose volume and labeling.
• Verify the Five Rights:
  – Right patient (tip: verify patient age)
  – Right vaccine
  – Right route
  – Right time
  – Right dose
• Triple check all vaccines before administration
Preventing Errors: Storage Labels

- Store unused vials or drawn-up syringes in a color-matched storage container.
- Label the bin/container. CDC has developed these for each brand and formulation. You will find the most up-to-date versions on the CDC’s [U.S. COVID-19 Vaccine Product Information](https://www.cdc.gov/vaccines/vpd/covid-19/product-information.html) pages for each formulation.
- Store look-alike or sound-alike vaccines on different shelves in the cold-storage unit or in different cold-storage units.
Preventing Errors: Considerations to Ensure Vaccine is not Expired

Tip #1:

- Use Beyond Use Date labels while vaccine is stored in the refrigerator.
- CDC has developed these for each brand and formulation. You will find the most up-to-date versions on the CDC’s [U.S. COVID-19 Vaccine Product Information](https://www.cdc.gov/vaccines/hcp/professionals/vaccination-schedules/schedules.html) pages for each formulation.
Preventing Errors: Considerations to Ensure Vaccine is not Expired

Tip #2:

- Mark the puncture information on the vial label
  - Record date and time of first vial puncture on the vial.
  - Store at the labeled temperature once punctured.
  - Discard after the number of hours allowed for the vaccine.
Preventing Errors: Considerations to Ensure Vaccine is not Expired

Tip #3:

• Label drawn-up syringes with the vaccine information, lot number, and post-dilution beyond use time.
• The vaccine preparer should initial the label.
• Color code the label.
• Example do-it-yourself syringe labels:

Pfizer BioNTech COVID-19 Ages 6m-4y
Lot ABCDEFG
Expiration: ______________ Init:____

Moderna COVID-19 Ages 6m-5y
Lot ABCDEFG
Expiration: ______________ Init:____
Preventing Errors: Safety when Multiple Vaccine Formulations are Stored in the Same Facility

• Additional considerations if drawing up multiple brands or formulations of vaccine at a facility:
  – Draw them up in different areas. Label and color code those areas.
  – Label any drawn-up syringes with color-matched labels.
  – Label transport containers with color-matched labels.
  – Consider hanging posters or reminders.
  – If any documentation is paper-based, consider printing information or forms on color-matched paper.
Look-Alike-Sound-Alike Labeling

• Label vaccine storage containers, boxes and vials with Look-Alike-Sound-Alike (LASA) stickers.
  – Consider using the method you currently use for other LASA labeling.
  – If needed, pre-printed LASA stickers are available online or through your usual supply chains. Examples are shown below.

• Store look-alike or sound-alike vaccines on different shelves or in different cold-storage units.
• ACIP meetings occurring June 17th and 18th
Ordering IDPH (for locations outside of Chicago)

• Deliveries for Phase 1 Pre-orders (responses due 6/7/22) are expected to between June 20th through June 24th (estimated) assuming FDA authorization(s) and CDC recommendation(s) occur no later than June 18th

• Phase 2 pre-ordering is open (responses due 6/13/22) are expected between June 23rd through June 29th (estimated) assuming FDA authorization(s) and CDC recommendation(s) occur no later than June 18th

• It is expected after these dates orders can be placed through I-CARE directly (provided vaccines are authorized and recommended)

Vaccines cannot be administered until CDC authorization
Ordering CDPH (for locations in Chicago)

- Pediatric providers were invited to pre-order June 16, 2022 (due June 23, 2022)
- Wider survey for ordering will be sent out Friday, June 24, 2022

Vaccines cannot be administered until CDC authorization
Reducing Pain When Vaccinating

By: Viktoria De Jong, Certified Child Life Specialist
Impact of Pain

**For Individuals**
- Dissatisfaction with care
- Increased likelihood of developing a needle fear
- Unnecessary suffering
- Future noncompliance behaviors
- Sub-optimal health outcomes

**For Health Care Providers**
- Inadequate quality of care delivered
- Increased likelihood for providers to have dissatisfaction with their job
- Noncompliance behaviors for providers
- Sub-optimal health outcomes
Working to Minimize Needle Pain and Fear

• **Physical**- Physical interventions work through The Gate Control Theory. Physical stimulation alters the transmission of pain messages to the brain at the spinal level, interfering/blocking the transmission by interfering with the pain impulses.

• **Psychological**- Cognitive behavioral therapy is a well-established and empirically supported treatment for procedure related pain in children and adolescents. Distraction is the most common type of cognitive-behavioral method to pain management.

• **Pharmacological**- Pain prevention options such as Pain Ease, EMLA, Sweet Ease and Buzzy are used to decrease pediatric distress for the more common procedures children experience such as immunizations and venipuncture.
Physical Interventions

- Comfort Positioning
  - Back to Chest:
  - Sideways Lap Sitting:
Physical Interventions

• Comfort Positioning

Chest to Chest:

Swaddled/Cradled (for a baby):
Psychological Interventions

- Distraction helps provide an alternate focus for a child during an uncomfortable or anxiety provoking procedure.

- Distraction is a form of positive coping. Offering distraction gives the child a sense of control and during a time of stress, simply having the opportunity to choose how they want to cope with the procedure can be an empowering experience.

- Clinical staff/vaccinators should avoid excessive reassurance and false suggestions ("it won't hurt"), as this promotes mistrust in children.
Helping Babies Cope with Painful Procedures- Babies may benefit from using these strategies to manage pain that is unique to their developmental needs.

**The 4 S’s Calming Strategy:**

**Swaddle** – This will provide a snug feeling of safety. Untuck only the arm or leg needed for the procedure. Swaddling your infant with their hands brought up towards their face can promote self-soothing behaviors.

**Shhhh** – It is important to match your shushing to the intensity of baby's crying, and to do so close to the ear. As baby becomes more calm, you can decrease the intensity. There should only be one person shushing to prevent overstimulation.

**Swaying** – Support your baby’s head and neck and gently jiggle him/her like a quiver. These movements should not be more than 1-2 inches side to side. Repetitive stimulation such as gently patting, or stroking your baby can also be calming.

**Sucking** – Offer your baby a pacifier, bottle, or breast to encourage sucking. This lowers stress (blood pressure, heart rate) and can trigger release of pain relieving chemicals in the brain.

*Please work with the parent or caregiver to identify the best ways to support the child*
Helping 12 months to 4-year-olds Cope with Pain

Distraction During a Painful Procedures- Active distraction allows a child to be involved in the experience while diverting their attention towards an activity or item.

Examples:
• Play with a favorite toy or stuffed animal
• Use light-up or interactive toys
• Read a book
• Sing songs or play music

• Look at I-Spy Books
• Play a game on an I-Pad/Tablet
• Do deep breathing exercises
• Squeeze a stress ball
• Ask the child questions “What is your favorite color?” “Who is your favorite character?”
Pharmacological Interventions

- Sweet-ease is most often given to infants 6 months and younger (can be given all the way to 12 months). Sweet-ease works best if given two minutes before the procedure starts.

- Pain Ease Spray can be used for children 4 and up (not for children with Sickle Cell or poor circulation). Pain Ease should be used in conjunction with an antiseptic and should be sprayed on right before a needle stick as it is very fast acting.

- Buzzy is for children older than 12 months. Buzzy should be held 3 inches above where the needle stick is occurring (it should be held there throughout the whole procedure).
With continued effort, undertreated pain and unfavorable outcomes can be avoided!

- For those of you who have Child Life Specialists employed at your facility, please try to include them in the planning/execution of vaccine events you may be hosting.

- For providers who do not have a Child Life Specialist, I am a free resource, I am able to further educate staff and provide suggestions on best practices in regards to pediatric pain management.
Parent/Caregiver handout [here](#)

Questions?
Email: [Viktoria.dejong@cityofchicago.org](mailto:Viktoria.dejong@cityofchicago.org)
References


References


References


*Pediatric emergency care at Medical City Children's Hospital.* Medical City Children's Hospital. (n.d.). Retrieved April 4, 2022, from https://medicalcityhealthcare.com/specialties/pediatric-emergency-care/?location=medical-city-childrens-hospital


**Contact Information**

**IDPH**
- To enroll in I-CARE: dph.immunizations@illinois.gov
- For questions about vaccine orders: dph.vaccines@illinois.gov

**CDPH**
- Kevin Hansen: Kevin.Hansen@cityofchicago.org
- Provider resources: https://www.chicagohan.org/covid-19-vaccine/provider

**ICAAP**
- Stephanie Atella: satella@illinoisaap.com
- Facts@ilvaccinates.com

**Pfizer**
- Customer Service: Call 1-800-879-3477
- General Product Inquiries: Call 1-877-829-2619
- Pfizer Medical Information: Call 1-800-438-1985 or Visit PfizerMedicalInformation.com
- Controlant Customer Support: 1-701-540-4039
- Pfizer US Shipment Support: Call 1-800-666-7248

**Moderna**
- Customer Service: Call 1-866-MODERNA (1-866-663-3762) or Email ModernaPV@modernatx.com
- Chatbot here
Thank you!